Tighter blood pressure target may slash heart risks in hormone disorder

NCT ID NCT07673445

Not yet recruiting Disease control Sponsor: Chongqing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial compares two blood pressure targets in people with primary aldosteronism, a hormonal condition that causes high blood pressure. One group aims for a systolic pressure below 120 mmHg (intensive), the other between 120 and 140 mmHg (standard). Over 6 to 10 years, researchers track heart attacks, strokes, and other cardiovascular events to see if tighter control offers greater protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antihypertensive medications
What this could lead to: If intensive control works, it could establish a new, more effective blood pressure target to prevent heart attacks and strokes in people with primary aldosteronism.
What could go wrong: This is a large but early-stage comparison; intensive control may cause more side effects like dizziness or fainting, and the benefit over standard care may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY ALDOSTERONISM

Contacts and locations

Locations

the First Affiliated Hospital of Chongqing Medical University

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.